Enhancing Patient Safety Saves Hospitals Millions: Learn How Much Yours Could Save

As COVID-19 and the unprecedented patient care challenges it brought to healthcare organizations recede, hospitals are still reeling from financial strains caused by the pandemic. The AHA estimates that hospitals will lose between $53 billion and $122 billion by the end of this year due to residual effects of COVID-19, depending on vaccine distribution and return of patient volumes.

Still, this is no time for hospitals to hit the brakes on patient safety improvements, even if stepping up patient safety initiatives may seem challenging in the face of significant financial losses. In fact, patient safety and a healthier bottom line go hand-in-hand; if you improve patient safety, your margins will also improve, and for hospitals to return to pre-pandemic patient volumes, it will be vital for hospitals to demonstrate that patient safety is a priority.

Calculating the Value

Healthcare consultancy Sage Growth Partners recently conducted an economic value assessment of the patient-safety enhancing features and functionalities of our clinical surveillance platform.

The assessment—which is based on metrics and reports from peer-reviewed studies, journals, government databases, and other sources—determines a hospital’s potential savings from implementing VigiLanz. The evaluation is customized based on factors such as annual inpatient admissions, number of staffed beds, and daily census.

The assessment found that most hospitals can save millions of dollars by implementing VigiLanz. For example, a small hospital with 50 staffed beds, 3,000 annual admissions, an average daily census of 30, and a bed utilization rate of 50 percent could experience $1.3 million in savings. A large hospital, with 900 staffed beds, 40,000 annual admissions, an average daily census of 700, and a bed utilization rate of 80 percent, could gain $15.5 million in savings.

Hospitals can input their own unique data in order to instantly receive a free, customized report. The report shows the total economic impact the hospital could experience, and it breaks that impact down by potential:

  1. Cost savings, due to faster and more proactive identification of opportunities to cut costs, such as IV to PO conversions and more optimal management of high-cost drugs.
  2. Cost avoidance, due to fewer costly events such as hospital acquired infections or conditions, acute kidney injuries due to antibiotic use, adverse drug events, readmissions, and return visits to the emergency department.
  3. Returned resources, the value of time saved by transitioning from manual to automated processes.

The tool also provides a breakdown of savings by area, such as pharmacy, infection prevention, and safety and quality.

To learn more and to get your custom savings report, please check out the tool. If you have any questions or are interested in learning more about how your hospital can use VigiLanz to improve patient safety and your bottom line, contact us today.

Riverside University Health System Uses VigiLanz for NICU Antimicrobial Stewardship

Customer Profile 

Riverside University Health System Medical center

Riverside University Health System Medical Center (RUHS), a 439-bed facility in Moreno Valley, California, is committed to delivering exceptional care—and its quality performance reflects that commitment. Recognized by The Joint Commission as a top performer on key quality measures, RUHS has received awards from the American Heart Association/American Stroke Association. It is also recognized as a Baby Friendly Hospital by the World Health Organization and the United Nations Children’s Fund.


As part of its commitment to providing optimal patient care, RUHS participates in the California Perinatal Quality Care Collaborative, a statewide network of California’s neonatal intensive care units (NICUs) and high risk infant follow-up clinics. In 2016, the collaborative launched an antibiotic stewardship (ASP) initiative with 28 NICUs, including RUHS.

At that time, RUHS had an antimicrobial stewardship program (ASP) for all patients, but it did not have a program that was focused solely on pediatric and NICU patients. “As we looked more closely at the younger patient population, we realized there was room for improvement in this area,” said Nikita Patel, Assistant Director of Pharmacy–Clinical Programs & Quality Improvement at RUHS.

She noted that, while there are established clinical practice guidelines for neonatal early onset sepsis management, they can contribute to higher antibiotic use—sometimes unnecessarily.

“If a baby has an active infection the first two to three days of life, the mortality outcomes are staggering and antibiotic use can be life-saving,” said Patel. “But unnecessary antibiotic use can disrupt a baby’s gut microbiome and impact their long-term immune response. This puts them at a higher risk of developing chronic diseases like asthma, and can lead to antibiotic resistance.”


RUHS turned to VigiLanz to support its efforts to optimize antibiotic use among pediatric and NICU patients. The clinical surveillance solution—which continuously gathers information from the medical center’s EMR and other sources, analyzes that data in real time, and provides meaningful insights to healthcare providers—enables pharmacists to view robust antimicrobial utilization reports. “The reports help us continuously monitor antimicrobial use and assess prescribing trends,” said Patel.

VigiLanz also provides relevant healthcare providers with real-time alerts that promote ASP in the NICU. These alerts include:

  • 48-hour antibiotic timeouts that enable NICU pharmacists to review information and recent lab results on relevant patients.
  • Positive lab results, so that pharmacists more quickly review critical labs and make appropriate medication change recommendations or antibiotic de-escalation.
  • Pharmacokinetic monitoring alerts, so that pharmacists can immediately make recommendations regarding dosage changes.
“I can’t emphasize enough how valuable VigiLanz is for us. It helps drive timely and important patient care interventions and improves our efficiency and documentation.” – Nikita Patel, Assistant Director of Pharmacy – Clinical Programs & Quality Improvement, RUHS


The new approach to ASP at RUHS has had a significant positive effect on patient care, said Patel. “I can’t emphasize enough how valuable VigiLanz is for us,” she said. “It helps drive timely and important patient care interventions and improves our efficiency and documentation.”

Two noteworthy outcomes of the new approach include:

  • A 37% decrease in NICU antibiotic utilization between March 2017 and March 2018. Importantly, that 37% drop has also been sustained since 2018.
  • More than 90% compliance with 48-hour antibiotic timeouts for all patients admitted to the NICU and initiated on antimicrobials.

VigiLanz also saves pharmacists time, which also benefits patient care, said Patel. “We no longer have to manually review patient lists and data every day,” she explained. “VigiLanz automatically sorts relevant data for us and alerts us when there’s a potential problem or when there’s something new to review. That helps us intervene more quickly and spend more time on other patient care improvement initiatives.”


To learn more about how VigiLanz helps hospitals improve their patient safety and clinical surveillance, visit https://vigilanzcorp.com/ today.

Freeman Health System Uses VigiLanz to Enhance MRSA Screening, Reduce Vancomycin Use

Customer Profile

Freeman Health System, a 485-bed, three-hospital system in Joplin, Missouri, serves an area of 450,000 people across Missouri, Arkansas, Kansas, and Oklahoma. It is the #1 hospital in Southwest Missouri and the #4 hospital in Missouri, according to U.S. News & World Report.


Hospitals across the country are fighting to combat antibiotic overuse, resistance, and unwanted side effects, but many are struggling to implement new and effective workflows that help meet these goals. Much of the challenge boils down to speed and efficiency—hospitals need to identify antibiotic overuse more quickly, and intervene sooner when it does occur.

Freeman Health System is no exception to the challenges associated with antimicrobial stewardship (ASP), and it was looking for a way to improve its ASP processes, particularly related to vancomycin use among patients with pneumonia.

“Data shows that 98 percent of the time, a negative MRSA screen for a patient with pneumonia means that a patient does not have MRSA-pneumonia, and their empiric vancomycin therapy can safely be discontinued,” said Adrienne Carey, PharmD, BCPS, Clinical Pharmacist and Data Mining Program Manager at Freeman Health System. “We wanted to streamline our MRSA screening process so that we could more quickly identify if a MRSA screen is negative, and therefore, discontinue vancomycin use sooner.”


Freeman Health System’s antibiotic stewardship team had already changed the health system’s pneumonia pathway orders to ensure all patients who came into the ER automatically received a nasal screen for MRSA.

“Our pharmacy department was tasked with educating physicians about the change and with contacting them with the results,” said Carey. “The goal was to de-escalate patients’ antibiotics more quickly.”

The problem was that results were not always communicated quickly to pharmacists, so there was sometimes a delay in identifying patients whose vancomycin therapy could be discontinued.

Freeman Health System turned to VigiLanz to help, working with the VigiLanz clinical support team to create a negative MRSA screen rule within the system. Now, whenever a patient prescribed vancomycin has a negative MRSA screen and no other cultures are positive for MRSA, the pharmacy team and infectious disease physician receive an alert in real time.

“Before implementing the VigiLanz rule, we had to manually run reports through our health information system to view all patients on vancomycin, then check each patient’s microbiology results to see if they had been screened for MRSA,” said Carey. “That took a lot of time.”

Now, pharmacists and physicians can more quickly discontinue vancomycin use and switch to an alternate antibiotic when appropriate, she explained. “We are not leaving our patients on vancomycin any longer than necessary.”

Adrienne Carey, PharmD, BCPS describes real-time alerts helping pharmacists


In the first six months since November 2018, when the new workflow was implemented, Freeman Health System’s pharmacists worked with physicians to discontinue vancomycin therapy in 70 patients.

Other key benefits of the new approach include:

  • Time savings for pharmacists
  • Time savings for nurses by reducing doses and drawing fewer labs
  • Monetary savings by reducing unneeded antibiotics
  • Reduced risk of infection through an IV route since IV lines are discontinued sooner due to de-escalation
  • Fewer medication side effects
  • Less chance for antibiotic resistance
  • Improved patient satisfaction due to fewer medications being administered
  • Shorter lengths of stay

“Building this rule and receiving immediate alerts from VigiLanz is helping us better identify all patients who qualify to have their therapy de-escalated and do so in a timely fashion,” said Carey. “We have also seen a trend toward less vancomycin usage overall.”

Related Resource:

Technology Can Help with Vancomycin Dosing

Pharmacy Practice News recently interviewed Houston Methodist Hospital about how they are using VigiLanz precision dosing powered by DoseMeRx to gain instant access to personalized dosing for vancomycin and other antimicrobials. Here’s an excerpt:

Technology Can Help With Vancomycin Dosing

By AI Heller

Houston Methodist Hospital (HMH) is leading a shift this September toward AUC (area under the curve) antimicrobial dosing in all eight facilities of the Houston Methodist health system, said William L. Musick, PharmD, BCIDP, a clinical specialist in infectious diseases at HMH’s 1,200-bed flagship location.

“We knew for almost two years this would be the direction of the new vancomycin guidelines, and the direction we had to move,” Dr. Musick said.

Click here to read the full Pharmacy Practice News article.  

Economic Value Tool – Calculate Your Savings

Healthier Patients, Healthier Bottom Line

Calculate Your Savings
See how your hospital or health system could be using VigiLanz to save millions by optimizing efficiency and improving patient safety.

VigiLanz leads to savings throughout your health system—from the pharmacy department, to infection prevention, to overall quality and safety.

We’ve designed this calculator to provide insight into VigiLanz’s high economic impact. VigiLanz improves workflow and staffing efficiency, reduces and prevents costly safety errors and adverse events, and identifies cost-savings opportunities such as IV to PO conversions.

The tool starts with national benchmark data, but allows you to enter your own organization’s information for a more customized analysis. See your hospital’s potential savings in key areas, plus, receive a full report to see hospital-wide savings and a detailed description of the key savings drivers and methodology.

Hospital Patient Safety Report: Antimicrobial Stewardship

To better understand the state of hospital patient safety and the biggest opportunities for improvement, VigiLanz commissioned Sage Growth Partners, a healthcare consultancy, to conduct an independent survey of 100 hospital and health system leaders in February 2020.

View the full report here.

This infographic highlights some of the most noteworthy antimicrobial stewardship-related survey findings. The infographic reveals:

  • How hospital leaders rate their antimicrobial stewardship efforts
  • Where antimicrobial stewardship falls on their list of top safety priorities

How they are using technology to support their efforts

VigiLanz Ranked No. 1 by KLAS Research Across Three Categories for the Third Year

Clinical surveillance company recognized again as a KLAS leader in antimicrobial stewardship, infection control and monitoring, and pharmacy surveillance


MINNEAPOLIS – Feb. 4, 2020 – VigiLanz, a clinical surveillance company, today announced that it has earned 2020 Category Leader designations from KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the second year VigiLanz has been recognized by KLAS as a Category Leader across all three areas, and the third year to earn that distinction in Infection Control and Monitoring and Pharmacy Surveillance, prior to the Antimicrobial Stewardship category being added in 2019.

Three VigiLanz products were recognized in the “2020 Best in KLAS: Software and Services” report, released on January 31:

VigiLanz Dynamic Infection Control Monitor

Earning a score of 92.7, the Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s EHR. Its automatic exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“I really like the ability to adapt the rules in Dynamic Infection Control Monitor. Interpreting rules is much easier now than it was with our last system. My infection control team is not super tech savvy, and my people have other tasks and jobs to worry about. The system makes doing their jobs easy for them.”

  • Manager, August 2019, klasresearch.com

VigiLanz Dynamic PharmacoVigilance

Earning a score of 92.8, Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“The versatility of the VigiLanz system is its strength. We have been able to leverage rule abilities on many fronts. The product is excellent. It does a great job with tasking and the workflow of identifying patients. The product is very robust.”

  • Analyst/Coordinator, August 2019, com

VigiLanz Antimicrobial Stewardship

Earning a score of 93.3, the Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, drug-bug mismatches, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and provides direct reporting to the Centers for Disease Control’s National Healthcare Safety Network.

“VigiLanz doesn’t provide software where we have to fill in the blanks. The software has a framework that allows us to create our own world. The software is limitless. In this ever-changing world, the VigiLanz product is what we need for healthcare.”

  • Director, November 2019, klasresearch.com

“Our customers’ trust in our clinical surveillance products is the highest level of affirmation we can achieve,” said VigiLanz Chairman and CEO David Goldsteen, MD. “We strive to exceed our customers’ expectations year over year. We are proud to be recognized as a Category Leader for three years running. To the customers who asserted their confidence in us and our products – thank you. We will continue to set the bar higher and support you in building healthier hospitals.”

The KLAS Category Leader designation is awarded to vendors that lead select market segments in which at least two products meet a minimum number of KLAS Konfidence reviews. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.




About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.


About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

Real-time Antimicrobial Stewardship Improves Care at Intermountain Healthcare

Laurie Blankenship, PharmD, Pharmacy Director at Park City Hospital of Intermountain Healthcare, discusses the benefits of working with VigiLanz on a daily basis.

“I can remember five years ago, when we didn’t have VigiLanz or any kind of software for antimicrobial stewardship, and we didn’t have nearly as many good catches and we didn’t make nearly as many interventions,” says Blankenship.

Watch this short video to learn more about how Blankenship and her team are using VigiLanz to improve patient care.



I am the pharmacy director at Park City Hospital, which is one of the 23 hospitals at Intermountain Healthcare. It’s a community hospital, so it’s a little bit smaller. We only have 37 beds. Because of the size, I’m more of a working director. So I do a lot of clinical work. I do work with VigiLanz on a daily basis. I’m the co-chair of the Antimicrobial Stewardship Committee that we have at Park City Hospital.

I can remember five years ago when we didn’t have VigiLanz or any kind of software for antimicrobial stewardship and we didn’t have nearly as many good catches and we didn’t make nearly as many interventions.

VigiLanz helps keep us up to date on any cultures or results. So it’s the real time feature—so important because it gives us all that feedback right when it’s currently happening. Instead of looking through the medical chart and trying to find those blood cultures or the urine cultures, VigiLanz gives us that real time data. So it allows us to make more appropriate antibiotic choices, shortened duration of therapy, identify if there’s a bug drug mismatch and even identify discharged patients, which is a really big thing that we use it for. If the patient went home and their culture grew something that we need to change therapy, it’s a great tool for identifying those patients that are already out of our system.

My favorite part of working with VigiLanz is that we have all the information in one portal for antimicrobial stewardship. It includes our emergency room, it includes our ICU, it includes our med-surg, and all of it, again, is in real time. We have all that at our fingertips and an easily accessible tool to help us make the best decisions and to help us tailor and recommend, make awesome recommendations to physicians and to improve patient care. That’s the most important thing.

Adventist Health Uses VigiLanz to Curb Infections

Customer Profile

Adventist Health and Rideout, a nonprofit community-based health system in Marysville, California, provides services across the full spectrum of care, including general medical/surgery, intensive care, and cancer care. Comprised of an acute-care hospital and numerous medical centers, it is known for high quality and high patient satisfaction.


Hospitals across the country are experiencing high rates of hospital-acquired infections (HAIs). In fact, more than 800 health systems incurred reimbursement penalties from Medicare in 2019 because of too many HAIs, and one out of every 25 patients develops an infection while in hospitals, according to The Leapfrog Group.

Over the past few years, Adventist Health and Rideout has made reducing HAIs, particularly C. diff, a top priority. As a key part of this initiative, it has focused on reducing overprescribing of antibiotics, which is a common problem in hospitals, and which contributes to the rise in infections.

“We were struggling with overprescribing, with rates that exceeded the national average for similar hospitals of similar sizes,” explained Bryce Whitesides, PharmD, Pharmacy Operations Manager at Adventist Health and Rideout. “We were determined to improve our performance. We knew if we could improve, we’d see fewer infections.”


Before embarking on its initiative to curb HAIs, Adventist Health and Rideout was already using basic functions of VigiLanz’s platform to monitor patient care and fill in their EMR’s quality and reporting gaps. Still, Brock Taylor, PharmD, Clinical Manager at Adventist Health and Rideout, suspected the technology platform was underutilized.

“I spoke to our VigiLanz clinical support member who explained how we could use the technology to create more targeted and customized rules that would trigger alerts related to different types of data, such as prescribing data or lab data,” said Taylor. “The pharmacy team and infection prevention team then identified rules that we thought would be most helpful in monitoring and curbing infections.”

Now, pharmacists and physicians receive real-time alerts and if a red flag arises related to antibiotic prescribingfor example, if there is a mismatch between the medication ordered and the patient’s conditionpharmacists reach out to prescribing physicians to discuss the medication and determine if alternative approaches should be considered.

Closer Collaborations

As part of the Adventist Health and Rideout approach, pharmacists contact physicians for discussions when they receive alerts related to antibiotic prescribing. Initially, some physicians resisted this approach, so an infectious disease specialist (rather than pharmacists) began to initiate the contact with ordering physicians. “Over time, as physicians realized they could trust the alerts, they were willing to comply with the pharmacists’ recommendations—which helped drive down the rate of inappropriate antibiotic prescriptions,” said Whitesides.

To further ensure appropriate antibiotic use, Adventist Health and Rideout’s infectious disease specialist and pharmacy clinical manager receive alerts if physicians prescribe an antibiotic that has restricted indications, such as ceftazidime/avibactam. Again, when this occurs, they work with prescribing physicians to ensure the prescription is appropriate.

“We developed these rules strategically so that pharmacists could provide clinical interventions more quickly if necessary,” explained Whitesides. “We’re making sure that we don’t contribute to the rise in infections in hospitals or in the community after patients are discharged.”

Adventist Health and Rideout also uses VigiLanz to help pharmacists and infection prevention team members determine if an infected patient acquired their infection in the hospital or in the community prior to or after the hospital visit. That’s because VigiLanz sends alerts as soon as lab data indicates a patient has an infection, such as C. diff. Since pharmacists and infection prevention team members are notified so quickly, it’s easier for them to determine the origin of the infection.

As the hospital has become better at identifying the origin, pharmacists and infectious disease team members have found that many of the infections they would have traditionally reported as HAIs actually originated in the community, said Whitesides. As a result, the hospital has improved its quality metrics related to HAIs.

“Before it was difficult to know if a C. diff infection was hospital or community acquired,” he said. “Now, we can show how our antibiotic optimization is working, and demonstrate that we’re helping to lower the community-acquired C. diff rates. We’re not sending patients home with unnecessary or prolonged antibiotic prescriptions.”


The continued focus on appropriate use of antibiotics, and on the de-escalation of antibiotic use when appropriate, has improved patient care at Adventist Health and Rideout. It has also led to significant cost savings.

C. diff. infections have fallen from several monthly to approximately one every other month, and use of Zosyn and other broad-spectrum antibiotics has declined significantly, said Whitesides.

The the hospital is now meeting national standards for antibiotic utilization, and annual antibiotic usage expenditures have fallen $500,000 per year.

“Our finances have steadily improved over the past five years. While a number of initiatives have contributed to that, VigiLanz has played a large role.”
– Bryce Whitesides, PharmD, Pharmacy Operations Manager

Recently, Adventist Health West System, a large integrated health system which owns Adventist Health and Rideout, decided to replicate Adventist Health and Rideout’s more optimized use of VigiLanz throughout all of its hospitals. Now, there are more than 20 medical centers on the West Coast and Hawaii using VigiLanz to support their efforts to curb HAIs and optimize antibiotic use.

“VigiLanz is a very powerful tool that we’ve used to make very significant interventions, not only in our patients lives but the hospital at large,” said Whitesides. “The impact continues to grow.”


To learn more about how VigiLanz helps hospitals improve their patient safety and clinical surveillance, visit https://vigilanzcorp.com/ today.

IllumiCare and VigiLanz Partner to Help Pharmacists and Clinicians Advance Antimicrobial Stewardship

Houston Methodist Sugar Land Hospital first in country to launch new point-of-care alert solution with pharmacist-only rollout.

BIRMINGHAM, HOUSTON, & MINNEAPOLIS – February 6, 2018 – The CDC estimates that 20 to 50 percent of antibiotics prescribed in U.S. acute-care hospitals are unnecessary or inappropriate. With the need for healthcare systems and federal agencies to increase their focus on antibiotic stewardship, both providers and pharmacists play a vital role in monitoring safe and appropriate use. Today, VigiLanz, a clinical surveillance company, and IllumiCare, a leading provider of point-of-care technology, announce a partnership to increase visibility within providers’ and pharmacists’ normal workflows around antimicrobial therapy monitoring.

IllumiCare’s Smart Ribbon® is an EMR-agnostic, non-intrusive ribbon of information that hovers over the EMR and provides patient-specific information such as the costs and risks of medications and tests, opioid exposures, and more. The Smart Ribbon displays VigiLanz’s Antimicrobial Stewardship Solution in a more visible, convenient and accessible place in the EMR when the provider or pharmacist is making care decisions. With this ability to respond to context in real-time, the Smart Ribbon only delivers notifications on issues or opportunities that busy clinicians and pharmacists can personally act on. This increases engagement with the VigiLanz insights and saves pharmacists the time and energy often spent tracking down a clinical counterpart to resolve an activation that’s halting the workflow.

“One key element to promoting antimicrobial stewardship is making sure the information is easily accessible to the right clinician or pharmacist when they need it most,” said GT LaBorde, CEO of IllumiCare. “VigiLanz provides real-time information related to safe antibiotic use that can reduce overprescribing or inappropriate prescribing and ultimately, lower costs. By making this information not only easier to see and more actionable, but also appropriately tailored to the person taking the action, antimicrobial stewardship efforts will be more successful.”

Houston Methodist Sugar Land Hospital is the first health system to deploy the VigiLanz clinical surveillance alerts within IllumiCare’s Smart Ribbon. Pharmacists can choose to engage with VigiLanz activations by viewing them, marking them as necessary and providing comments, all within their current workflow in the EMR. One of the most important activations is the visibility of drug-bug mismatches, in which the antimicrobial a patient receives is not adequate for the microbiological organism presumed to be causing the clinical infection. Additionally, the VigiLanz alerts highlight broad antimicrobial use, de-escalation opportunities, and conversion opportunities to move the patient to an antibiotic that has equal efficacy but is less expensive, such as from IV drugs to oral medications.

“Having actionable insights into antimicrobial use is critical; being able to put those insights in front of clinicians and pharmacists at the point of care is industry-leading,” said David Goldsteen, MD, CEO of VigiLanz. “We’re thrilled to be partnering with IllumiCare to deliver our trusted clinical surveillance insights through their Smart Ribbon to those who take action, ensuring safe and appropriate antimicrobial use.”

For more information, visit Illumicare at www.illumicare.com and VigiLanz at www.vigilanzcorp.com